These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21833917)

  • 21. The new era of anticoagulation.
    Skeik N; Rumery KK; Rodriguez GT
    Ann Vasc Surg; 2014 Feb; 28(2):503-14. PubMed ID: 24412298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of oral versus intravenous phytonadione in patients with excessive anticoagulation.
    Key N
    Curr Hematol Rep; 2004 Sep; 3(5):315-6. PubMed ID: 15341696
    [No Abstract]   [Full Text] [Related]  

  • 23. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants.
    Liew A; Eikelboom JW; O'Donnell M; Hart RG
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S34-44. PubMed ID: 23790596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.
    Guo Y; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):71-8. PubMed ID: 23466969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome of self-management of oral anticoagulation in patients with atrial fibrillation or deep vein thrombosis.
    Heidinger KS; Bernardo A; Taborski U; Müller-Berghaus G
    Thromb Res; 2000 May; 98(4):287-93. PubMed ID: 10822075
    [No Abstract]   [Full Text] [Related]  

  • 26. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation.
    Watzke HH; Forberg E; Svolba G; Jimenez-Boj E; Krinninger B
    Thromb Haemost; 2000 May; 83(5):661-5. PubMed ID: 10823258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Has the era of warfarin terminated?].
    Pavlova TV; Dupliakov DV; Kuzina TN
    Angiol Sosud Khir; 2014; 20(1):16-20. PubMed ID: 24722016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.
    Lip GY
    Am J Med; 2011 Feb; 124(2):111-4. PubMed ID: 20887966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Self-control of long-term oral anticoagulation using a point-of-care device.
    Roudaut R
    Arch Cardiovasc Dis; 2008; 101(11-12):683-4. PubMed ID: 19059561
    [No Abstract]   [Full Text] [Related]  

  • 31. [New perspectives for anticoagulation in atrial fibrillation].
    Moser M; Bode C
    Dtsch Med Wochenschr; 2011 Sep; 136(39):1966-70. PubMed ID: 21935859
    [No Abstract]   [Full Text] [Related]  

  • 32. PORTALS: design of an innovative approach to anticoagulation management through eHealth.
    Talboom-Kamp EP; Verdijk NA; Talboom IJ; Harmans LM; Numans ME; Chavannes NH
    BMC Health Serv Res; 2017 Mar; 17(1):213. PubMed ID: 28302116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting oral anticoagulation.
    Weiner M
    Clin Pharmacol Ther; 2000 Jul; 68(1):4-5. PubMed ID: 10945309
    [No Abstract]   [Full Text] [Related]  

  • 34. Self-management of oral anticoagulation in the elderly: rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial.
    Siebenhofer A; Rakovac I; Kleespies C; Piso B; Didjurgeit U
    Thromb Haemost; 2007 Mar; 97(3):408-16. PubMed ID: 17334508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
    N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation.
    Pengo V; Cucchini U; Denas G; Davidson BL; Marzot F; Jose SP; Iliceto S
    Thromb Haemost; 2010 Feb; 103(2):442-9. PubMed ID: 20076843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Oral anticoagulation. What is vital in blood coagulation management? (interview by Dr. Judith Neumaier)].
    Sucker C
    MMW Fortschr Med; 2009 Mar; 151(12):48. PubMed ID: 19475860
    [No Abstract]   [Full Text] [Related]  

  • 39. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care.
    Rose AJ; Hylek EM; Berlowitz DR; Ash AS; Reisman JI; Ozonoff A
    Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):276-82. PubMed ID: 21505156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effective anticoagulation also in advanced age].
    Zimmermann W
    MMW Fortschr Med; 2015 Feb; 157(3):72. PubMed ID: 25743684
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.